<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937443</url>
  </required_header>
  <id_info>
    <org_study_id>Vanderbilt_University</org_study_id>
    <nct_id>NCT00937443</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure</brief_title>
  <acronym>EPCCHFWalk</acronym>
  <official_title>Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of heart failure grows as the population continues to age. Heart failure&#xD;
      incidence approaches 10 per 1,000 persons after the age of 65. Although pharmacotherapy&#xD;
      improves the treatment of heart failure it remains insufficient in preventing the progression&#xD;
      of this debilitating disease. Cell based therapy has gained great strides over the last&#xD;
      decade, launching cellular therapy into the mix of artillery for the treatment of chronic&#xD;
      heart failure and coronary disease. While early pre-clinical work demonstrates that stem cell&#xD;
      based therapy improves heart failure the exact mechanism in which these endothelial&#xD;
      progenitor cells (EPC's) are recruited from the bone marrow, proliferate under the mediation&#xD;
      of growth factors, and migrate to the injured tissues endogenously still remains obscured.&#xD;
      Therefore in order for clinicians and scientist to impact heart failure treatment, a greater&#xD;
      understanding of the physiological changes in EPC's and other modulators of cardioreparative&#xD;
      process need further investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure remains a devastating progressive chronic disease in which pharmacotherapy is&#xD;
      not often sufficient. Although cell based therapy is gaining publicity in the treatment of&#xD;
      coronary artery disease and heart failure. Determining how endothelial progenitor cells are&#xD;
      recruited, proliferate, and home to injured tissue is an important area of investigation.&#xD;
      Equally important is determining factors which improve EPC stimulation and efficiency such as&#xD;
      realistic levels of exercise and the modulation of various cardioreparative factors (VEGF,&#xD;
      NRG-1, and SDF-1) within heart failure patients. Since the endogenous repair mechanism is&#xD;
      down regulated in heart failure patients such efforts may uncover ways to tip the balance in&#xD;
      heart failure back to normal reparative maintenance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cells</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>exercise</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Walking Exercise Group</arm_group_label>
    <description>Walking Exercise Group versus Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Fitness</intervention_name>
    <description>Does intensity of aerobic walking exercise modify cardiac reparative factors</description>
    <arm_group_label>Walking Exercise Group</arm_group_label>
    <other_name>Quality of Life Questionnaires</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Walking Exercise Group</intervention_name>
    <description>Walking Group will increase intensity, duration, and steps of walking per week.</description>
    <arm_group_label>Walking Exercise Group</arm_group_label>
    <other_name>Quality of Life Questionnaires</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      60 ml of blood will be used to measure baseline levels of EPC's, NRG-1, VEGF, and SDF-1.&#xD;
      Repeat venipuncture will be done at Week 12. Approximately 60 ml of blood for the measurement&#xD;
      of EPC's, NRG1, VEGF, and SDF-1.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiac Heart Failure Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Subjects 30-65 years old.&#xD;
&#xD;
          2. Subjects able to give Informed Consent.&#xD;
&#xD;
          3. Subjects who will give permission for collection of clinical and demographic data from&#xD;
             the electronic medical records.&#xD;
&#xD;
          4. Subjects with symptomatic ischemic or non-ischemic heart failure in a stable condition&#xD;
             with New York Heart Association class II-III for at least the last 3 months before&#xD;
             study enrollment.&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; 40%.&#xD;
&#xD;
               -  Peak volume of oxygen utilization (peak VO2) of &lt; 25 ml/kg/min.&#xD;
&#xD;
          5. Patient on a stable dose of statin or who can be initiated on statin therapy.&#xD;
&#xD;
          6. Subjects with ischemic cardiomyopathy must have had either a negative stress test&#xD;
             within the last 6 months or a cardiac catheterization within the last year confirming&#xD;
             stable disease.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subjects with myocardial infarction or unstable angina within the last six months.&#xD;
&#xD;
          2. Subjects with symptomatic or severe aortic stenosis.&#xD;
&#xD;
          3. Subjects with severe HTN (SBP &gt; 180) or hypotension (SBP &lt; 100).&#xD;
&#xD;
          4. Subjects who are pregnant.&#xD;
&#xD;
          5. Subjects who have bone marrow suppression.&#xD;
&#xD;
          6. Subjects with exercise limiting peripheral arterial disease.&#xD;
&#xD;
          7. Subjects with history of ventricular tachycardia without an implantable defibrillator&#xD;
&#xD;
          8. Subjects with decompensated diabetes (HgA1c &gt;10).&#xD;
&#xD;
          9. Subjects with orthopedic limitations.&#xD;
&#xD;
         10. Subjects with any other clinical condition precluding regular participation in walking&#xD;
             exercise regimen.&#xD;
&#xD;
         11. Subjects who already participate in regular physical exercise regimen for greater than&#xD;
             30 minutes a day 5 days per week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas B Saywer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt Heart and Vascular Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Heart and Vascular Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physical Activity</keyword>
  <keyword>Cardiac Heart Failure</keyword>
  <keyword>Exercise Regimen</keyword>
  <keyword>Cardioreparative Factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

